PROBLEM TO BE SOLVED: To provide a medical use of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide.SOLUTION: There is provided a medical treatment of cognitive disorder in an alzheimer's disease patient or a schizophenic patient, wherein 0.1-3 mg oral daily dose of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or pharmaceutically acceptable salt thereof is administered to the patient. A target type of schizophenemia is optimally selected from paranoid, disorganized, tensional, and undifferentiated types. Moreover, the compound or its pharmaceutically acceptable salt is dosed to the patient in the oral daily dose of 0.1-3 mg. The compound is a therapeutic medicine capable of improving one or more of learning, delay memory, working memory, visual learning, processing speed, vigilance, language learning, social cognition, long-term memory, and executive functions.【課題】（Ｒ）－７－クロロ－Ｎ－（キヌクリジン－３－イル）ベンゾ［ｂ］チオフェン－２－カルボキサミドの新規医薬用途の提供。【解決手段】（Ｒ）－７－クロロ－Ｎ－（キヌクリジン－３－イル）ベンゾ［ｂ］チオフェン－２－カルボキサミド及びその製薬上許容しうる塩を、0.1 mg～3 mgの経口１日投与量で患者に投与するアルツハイマー病又は統合失調症の患者における認知障害の治療用医薬。統合失調症は好ましくは、妄想型、解体型、緊張型及び未分化型から選択される。また前記化合物及びその製薬上許容しうる塩を０．１ｍｇ～３ｍｇの１日の経口投与量で患者に投与する。学習、遅延記憶、作業記憶、視覚学習、処理速度、ビジランス、言語学習、社会的認知、長期記憶又は実行機能の一つ以上を改善する治療用医薬。【選択図】なし
